Get to know our clinical trials

Clinical trial with E7386 in combination with Pembrolizumab in previously treated patients with specific solid tumors.

PRIMARY OBJECTIVE: PHASE IB PART: - TO EVALUATE THE SAFETY AND TOLERABILITY OF E7386 IN COMBINATION WITH PEMBROLIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH SPECIFIC SOLID TUMORS - TO DETERMINE THE RECOMMENDED DOSE FOR PHASE 2 (DRF2) OF E7386 IN COMBINATION WITH PEMBROLIZUMAB PART PHASE 2: - TO EVALUATE THE OBJECTIVE RESPONSE RATE (ORR) OF E7386 IN COMBINATION WITH PEMBROLIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH SPECIFIC SOLID TUMORS (MELANOMA, RCC, HCC).

Status
In recruitment
headquarters
Madrid

Technical Summary

  • OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY WITH E7386 IN COMBINATION WITH PEMBROLIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH SPECIFIC SOLID TUMORS. IMMUNOTHERAPY.
  • Code EudraCT: 2021-001568-10
  • Protocol number: E7386-G000-201
  • Promoter: Eisai Inc.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.